Choose Health

How to Slow Down Geographic Atrophy Caused by AMD

National
|
December 3, 2025

Geographic Atrophy (GA), the advanced form of dry age-related macular degeneration (AMD), can irreversibly damage your eyes faster than you may think. When GA progresses, patches of damaged cells called “lesions” grow and can damage parts of your eye that help you read, drive, and recognize faces. SYFOVRE is the only FDA-approved GA treatment proven to slow GA lesion progression in as few as 6 treatments per year.*It’s important to know that GA cannot be stopped or reversed, but slowing GA lesion progression can help slow the damage it causes. SYFOVRE slows GA. Talk to your eye doctor about SYFOVRE today.*Administered by your doctor once every 25-60 days.

INDICATION AND IMPORTANT SAFETY INFORMATIONWhat is SYFOVRE®?SYFOVRE® (pegcetacoplan injection) is a prescription eye injection, used to treat geographic atrophy (GA), the dry advanced form of age-related macular degeneration (AMD).Who should NOT receive SYFOVRE?Do not receive SYFOVRE if you have an infection or active swelling in or around your eye that may include pain and redness, or are allergic to pegcetacoplan or any ingredients in SYFOVRE. SYFOVRE can cause serious allergic reactions such as trouble breathing, tongue, face, lips, or mouth swelling, rashes, and hives.SYFOVRE can cause serious side effects:

  • Eye infection (endophthalmitis) or separation of layers of the retina (retinal detachment)
    • Call your healthcare provider right away if you have eye redness, light sensitivity, eye pain, or any change in vision including blurred, wavy/distorted vision, small specks floating in your vision, or flashing lights
  • Severe inflammation of vessels in the retina which may result in severe vision loss. Call your healthcare provider right away if you have eye redness, light sensitivity, eye pain, or any change in vision including blurred, wavy/distorted vision, or flashing lights
  • Risk of developing wet AMD. You should be monitored for signs of wet AMD and you should report if you have any change in vision including blurred, wavy/distorted vision, black spots, or loss of central vision to your healthcare provider
  • Episodes of eye inflammation. You should report any symptoms including eye redness, light sensitivity, eye pain, small specks floating in your vision, or any changes in vision to your healthcare provider
  • Increase in eye pressure within minutes of the injection. Your healthcare provider will monitor this after each injection

Before receiving SYFOVRE:

  • Tell your healthcare provider if any of the following applies to you:
    • If you have a history of seeing flashes of light or small specks floating in your vision and notice a sudden increase of size and number of these specks
    • If you have high pressure in the eye or glaucoma
  • Tell your healthcare provider about all of your medical conditions, including
    • If you are, or think you are pregnant, breastfeeding, or are planning to have a baby, ask your doctor for advice before taking this medicine
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements

What should I avoid while receiving SYFOVRE?

  • After an injection or an eye exam, your eyesight may temporarily be impaired. Do not drive or use machinery until your vision recovers

What are the most common side effects of SYFOVRE?

  • Eye discomfort
  • Wet age-related macular degeneration
  • Small specks floating in vision
  • Blood in the white of the eye

These are not all the possible side effects of SYFOVRE. Tell your healthcare provider about any side effect that bothers you or does not go away.Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.Please see the SYFOVRE full Prescribing Information for more information.

APELLIS®, SYFOVRE® and their respective logos are registered trademarks of Apellis Pharmaceuticals, Inc. Other trademarks referenced herein are the property of their respective owners.©2025 Apellis Pharmaceuticals, Inc. 11/25 US-PEGGA-2500313 v1.0

Follow Us On Social
|
Instagram
|
YouTube
|
Facebook
|
TikTok